Penumbra Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.1%projected annual EPS growth
Analyst Coverage
12analysts covering
FY Revenue (est.)
$1.6Bnext fiscal year
FY EPS (est.)
$4.79next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Growth (YoY) Quarterly15.6%
Gross Margin Annually67.1%
Diluted EPS (TTM) Quarterly4.3
Watch Items
- Boston Scientific Acquisition Regulatory and Shareholder ApprovalsTrigger: Failure to obtain HSR clearance or shareholder vote rejectionAction: Re-evaluate standalone valuation; assess impact of the $525 million termination fee payable by Penumbra or $900 million payable by Boston Scientific.
- THUNDERBOLT Stroke Treatment System Commercial AdoptionTrigger: Slower-than-expected clinical uptake or competitive launches by Medtronic/StrykerAction: Adjust long-term neurovascular revenue growth projections and market share assumptions.
Research as of 2 Sep 2026